Ophthalmology

Eligibility criteria prevents more Black individuals than White individuals from participating in clinical trials for diabetic macular edema.

Durga S. Borkar, MD, MMCi, presented her study at AAO 2023 which found trial eligibility discriminates against race/ethnicity.

In the PULSAR study, White and Asian participants had similar best corrected visual acuity improvements in the 2 mg aflibercept group.

Presented at AAO 2023, Russell Van Gelder, MD, PhD, discussed Abacus study and how KIO-301 targets low vision and end stage retinitis pigmentosa with visual acuity of light perception.

Two studies presented at AAO demonstrate that low dose atropine is associated with slowing myopia progression, but another study finds that this is not true. Thus, there are mixed results on this relationship.

Patients who are female, in minority groups (particularly, Black or Asian), a visual acuity outside of the <20/40 to 20/200 range, and who are >70 years old receive less treatment.

On the floor at AAO 2023, host Veeral Sheth, MD, discusses UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.

Aflibercept 8 mg treatment did well with maintaining patients, according to a presentation focusing on the PULSAR study.

In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.

ARCHER study demonstrated that the antibody ANX007 was time and dose dependent, robust, and not dependent on lesion growth.

Without treatment, lesions > 500 µm away from the fovea will take anywhere from 3.07 years to 12.9 years to reach it. With pegcetacoplan treatment, the lesion will reach the fovea anywhere between 3.56 years – 15 years for monthly treatment and 3.47-14.6 years for treatment every other month.

Despite recommendations to consult with ophthalmologists prior to initiating semaglutide, the cardiometabolic drug was not found to be linked to worsened DR outcomes.

New AAO 2023 data suggests drugs like dapagliflozin and empagliflozin may provide greater protection against glaucoma than GLP-1 agonists or DDP-4 inhibitors.

New data from the Cleveland Clinic Cole Eye Institute showed patients not responding to anti-VEGF inhibitors could improve clinical and regimen parameters with short-term faricimab.

ChatGPT, Google Bard, and Bing Chat struggle with recommending practicing nearby ophthalmologists and disproportionate against females.

In the study from AAO 2023, patients with neovascular AMD who are on aflibercept injection treatment continued their treatments >12 weeks or 16 weeks.

Patients with RAO had a higher risk of death, stroke, and myocardial infarction at both short-term and long-term intervals compared to matched controls diagnosed with cataract.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

On October 27, 2023, the FDA warned consumers to stop using ophthalmic products from 6 brands, including CVS Health and Rite Aid, after investigators found bacterial contamination at a manufacturing facility.

Scleral buckling without PPV is effective for most patients with retinal dialysis and shows a low rate of cataract formation.

Most answers provided by ChatGPT-4 were consistently appropriate regarding vitreoretinal surgeries, including retinal detachments, macular holes, and epiretinal membranes.

Genentech announced the FDA had approved faricimab-svoa (Vabysmo) for retinal vein occlusion on October 26, 2023, which marks the third ophthalmic indication for the bispecific antibody.

Utilizing swept-source OCT, the analysis reports significantly thicker subfoveal choroidal thickness among patients with active disease than those with inactive disease.

Among an Egyptian cohort, isolated retinitis is the most common inherited retinal disease, followed by Stargardt, cone-rod dystrophy, autosomal recessive bestrophiniopathy, and the unspecified subtype.

Results revealed the inner lower and inner left subfields of the better eye were more strongly associated with vision-related quality of life than the worse eye.

An analysis of more than 700 videos on TikTok reveals new insight into the levels and purveyors of misinformation in the most popular ophthalmology content on the platform.

Many carriers reported feelings of concern, anxiousness, and guilt for passing the X-linked inherited retinal disease to their children—and 78% of respondents in a new study believe that carriers should have access to gene therapy options.

New data suggests retinal vein occlusion in individuals under 75 years of age correlates with increased dementia risk, while those older than 75 have a reduced risk.

Volume and frequency of alcohol consumption were associated with a greater risk of visual impairment and blindness among patients with newly diagnosed OAG.